Paul Feuerstadt

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 21

Top Venues

Infectious diseases and therapy

Expert review of anti-infective therapy

Therapeutic advances in gastroenterology

Digestive diseases and sciences

Gastroenterology Center of Connecticut

University of Pennsylvania (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Gastroenterology Center of Connecticut Nov 01 2011

United States

Attending Gastroenterologist :: Gastroenterology

Danbury Hospital Jul 10 2010 - Oct 24 2011

United States

Attending Physician :: Gastroenterology

Education History

University of Pennsylvania Sep 01 1996 - Jun 01 2000

United States

BSC :: School of Arts and Sciences

Publications

Whitfield L Knapple, David S Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA ® ) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection. Therapeutic advances in gastroenterology 17 (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Whitfield L Knapple, David S Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA ® ) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection. Therapeutic advances in gastroenterology 17 (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Paul Feuerstadt, Teena Chopra, Whitfield Knapple, Nicholas W Van Hise, Erik R Dubberke, Brian Baggott, Beth Guthmueller, Lindy Bancke, Michael Gamborg, Theodore S Steiner, Daniel Van Handel, Sahil Khanna
PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Abdelkader Chaar, John Damianos, Rabia Rizwan, Houssam Al-Nahhas, Muhammad Sohail Mansoor, Prabin Sharma, Umer Malik, Paul Feuerstadt
First Clostridioides difficile Recurrence Is Highest Following Concomitant Antimicrobial Administration During and Within 30 Days of Treatment. Digestive diseases and sciences (2023)
Paul Feuerstadt
Where does RBX2660 fit within clinical practice? Expert review of anti-infective therapy (2023)
Paul Feuerstadt
Where does RBX2660 fit within clinical practice? Expert review of anti-infective therapy 21 (3) (2023)
Christine Lee, Thomas Louie, Lindy Bancke, Beth Guthmueller, Adam Harvey, Paul Feuerstadt, Sahil Khanna, Robert Orenstein, Erik R Dubberke
Safety of fecal microbiota, live-jslm (REBYOTA ™ ) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therapeutic advances in gastroenterology 16 (2023)
Paul Feuerstadt
Where does RBX2660 fit within clinical practice? Expert review of anti-infective therapy 21 (3) (2023)
Paul Feuerstadt
Where does RBX2660 fit within clinical practice? Expert review of anti-infective therapy (2023)
Paul Feuerstadt
Where does RBX2660 fit within clinical practice? Expert review of anti-infective therapy (2023)
Paul Feuerstadt
Where does RBX2660 fit within clinical practice? Expert review of anti-infective therapy 21 (3) (2023)
Paul Feuerstadt, Olga C Aroniadis, Felicia L Svedlund, Mariana Garcia, Laura Stong, Mena Boules, Sahil Khanna
Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Digestive diseases and sciences (2021)
Abdelkader Chaar, Paul Feuerstadt
Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. Therapeutic advances in gastroenterology 14 (2021)
Paul Feuerstadt, Simon J Hong, Lawrence J Brandt
Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection. Digestive diseases and sciences 65 (2) (2019)
Ziga Vodusek, Paul Feuerstadt, Lawrence J Brandt
Review article: the pharmacological causes of colon ischaemia. Alimentary pharmacology & therapeutics 49 (1) (2018)

Paul Feuerstadt.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Paul Feuerstadt